Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Wed, 12-Aug 5:00 PM ET)
TipRanks (Wed, 12-Aug 7:40 AM ET)
Wall Street Analysts Are Neutral on Top Healthcare Picks
TipRanks (Sun, 9-Aug 12:50 PM ET)
Travere Therapeutics to Participate at Upcoming Investor Conferences
Business Wire (Wed, 5-Aug 4:30 PM ET)
Market Chameleon (Wed, 5-Aug 7:49 AM ET)
Travere Therapeutics Reports Second Quarter 2026 Financial Results
Business Wire (Tue, 4-Aug 4:01 PM ET)
Travere Therapeutics to Report Second Quarter 2026 Financial Results
Business Wire (Tue, 28-Jul 4:30 PM ET)
Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm
PRNewswire (Mon, 27-Jul 8:50 AM ET)
Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027
Business Wire (Tue, 16-Jun 4:30 PM ET)
Business Wire (Thu, 4-Jun 10:09 AM ET)
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
Travere Therapeutics trades on the NASDAQ stock market under the symbol TVTX.
As of August 13, 2026, TVTX stock price declined to $61.43 with 1,236,992 million shares trading.
TVTX has a beta of 2.00, meaning it tends to be more sensitive to market movements. TVTX has a correlation of 0.15 to the broad based SPY ETF.
TVTX has a market cap of $5.71 billion. This is considered a Mid Cap stock.
Last quarter Travere Therapeutics reported $170 million in Revenue and -$.10 earnings per share. This beat revenue expectation by $10 million and missed earnings estimates by -$.33.
In the last 3 years, TVTX traded as high as $66.24 and as low as $5.12.
The top ETF exchange traded funds that TVTX belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWO.
TVTX has outperformed the market in the last year with a price return of +252.8% while the SPY ETF gained +22.2%. TVTX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +43.4% and +10.6%, respectively, while the SPY returned +5.6% and +6.6%, respectively.
TVTX support price is $60.41 and resistance is $63.92 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TVTX shares will trade within this expected range on the day.